Immuneering Corp (IMRX): Total Assets
$231.99M
As of 2025-12-31
$202.06M
As of 2026-06-30
+23.8%
3-year compound annual growth
+43.3%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $231.99M | +340.1% | 2026-03-06, Balance as of period end |
| 2024-12-31 | $52.71M | -48.6% | 2026-03-06, Balance as of period end |
| 2023-12-31 | $102.58M | -16.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $122.37M | -26.6% | 2024-03-01, Balance as of period end |
| 2021-12-31 | $166.70M | +333.9% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $38.42M | n/a | 2022-03-10, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Immuneering Corp (IMRX) | 2025-12-31 | $231.99M | +340.1% |
| Oramed Pharmaceuticals Inc. (ORMP) | 2025-12-31 | $230.86M | +48.7% |
| Design Therapeutics, Inc. (DSGN) | 2025-12-31 | $226.20M | -10.3% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $225.87M | -2.9% |
| Pliant Therapeutics, Inc. (PLRX) | 2025-12-31 | $225.23M | -43.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $224.95M | +195.8% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $239.34M | -5.8% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $240.29M | +574.7% |
| Abeona Therapeutics Inc. (ABEO) | 2025-12-31 | $219.57M | +101.6% |
Compare IMRX, ORMP, DSGN, EOLS side by side · Screen every company in Pharmaceutical Preparations ↗